Therapeutic approach of primary bone tumours by bisphosphonates

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 2981-2987

  Moriceau, G ^a,b   Ory, B ^c   Gobin, B ^a,b   Verrecchia, F ^a,b   Gouin, F ^a,b,d   Blanchard, F ^a,b   Redini, F ^a,b   Heymann, D ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HÔTEL DIEU   (France)

Author keywords

Bisphosphosphonates; Giant cell tumor of bone; Primary bone tumors; Sarcoma

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; IFOSFAMIDE; MEDRONATE TECHNETIUM TC 99M; MINODRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; BONE SCINTISCANNING; BONE TUMOR; CANCER COMBINATION CHEMOTHERAPY; CHONDROSARCOMA; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; EWING SARCOMA; HUMAN; NONHUMAN; OSTEOCLASTOMA; OSTEOLYSIS; OSTEOSARCOMA; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CHONDROSARCOMA; DIPHOSPHONATES; DRUG DESIGN; GIANT CELL TUMOR OF BONE; HUMANS; OSTEOSARCOMA;

EID: 78649841532     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563554     Document Type: Review

References (105)

1. Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704: & 49-57.
2. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Exp 2000; 10: 159-78.
3. Heymann D, Ory B, Gouin F, Green JR, Rédini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004; 10: 337-43.
4. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59.
5. Hirbe AC, Roelofs AJ, Floyd DH, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009; 44: 908-16.
6. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269-80.
7. Silberstein EB, Saenger EL, Tofe AJ, Alexander GW, Park HM. Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiography. A comparison of sensitivity. Radiology 1973; 10: 551-5.
8. Rajarubendra N, Lawrentschuk N. Imaging of Bone Metastatis. In: Bone cancer: progression and therapeutic approaches. Heymann Dominique, Academic Press. Chapter 2010; 23: 270-82.
9. Schirrmeister H, Arslandemir C, ed. Diagnosis of skeletal metastases in malignant extraskeletal cancers. In: Bone cancer: progression and therapeutic approaches. Heymann Dominique; Ed. Academic Press, Chapter 2010; vol. 24: pp. 283-94.
10. Hoefnagel CA, Bruning PF, Cohen P, Marcuse HR, van der Schoot JB. Detection of lung metastases from osteosarcoma by scintigraphy using 99mTc-methylene diphosphonate. Diagn Imaging 1981; 50: 277-84.
11. Fellner M, Baum RP, Kubíček V, et al. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010; 37: 834.
12. Anada T, Takeda Y, Honda Y, Sakurai K, Suzuki O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg Med Chem Lett 2009; 19: 4148-50.
13. Eisenhut M. Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases: I. Organ distribution and kinetics of I-131 BDP3 in rats. J Nucl Med 1984; 25: 1356-61.
14. Tsushima N, Yabuki M, Harada H, et al. Tissue distribution and pharmacological potential of SM-16896, a novel oestrogenbisphosphonate hybrid compound. J Pharm Pharmacol 2000; 52: 27-37.
15. Syed R, Bomanji J, Nagabhushan N, et al. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma. J Nucl Med 2006; 47: 1927-35.
16. Gupta R, Seethalakshmi V, Jambhekar NA, et al. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 2008; 12: 239-48.
17. Flanagan A, Tirabosco R, Gikas P. Osteoclast-rich lesions of bone: a clinical and molecular overview. In: Bone cancer: progression and therapeutic approaches. Heymann Dominique, Ed. Academic Press. Chapter 2010; vol. 18: pp. 211-24.
18. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 2006; 30: 484-9.
19. Atkins GJ, Haynes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner Res 2000; 15: 640-9.
20. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961-78.
21. Ory B, Moriceau G, Redini F, Heymann D. mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem 2007; 14: 1381-7.
22. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner Res 2000; 15: 1467-76.
23. Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone proteincoated surfaces. Calcif Tissue Int 1998; 63: 230-5.
24. Wang XM, Yu SF, Yang ZP. Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. Chin J Dent Res 2000; 3: 26-32.
25. Cheng Y, Huang L, Kumta S, Lee KM, Lai FM, Tam JSK. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 2003; 27: 385-91.
26. Chang SS, Suratwala SJ, Jung KM, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 2004; 426: 103-9.
27. Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004; 75: 71-7.
28. Zwolak P, Manivel JC, Jasinski P, et al. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am 2010; 92: 162-8.
29. Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai 2008; 91: 1609-12.
30. Fujimoto N, Nakagawa K, Seichi A, et al. A new bisphosphonate treatment option for giant cell tumors. Oncol Rep 2001; 8: 643-7.
31. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008; 42: 68-73.
32. Gibbons CLMH, Petra M, Smith R, Athanasou NA. Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone. Sarcoma 2003; 7: 35-41.
33. Hauben E, Hogendoorn P. Epidemiology of primary bone tumors and economical aspects of bone metastases. In Bone cancer: progression and therapeutic approaches, Heymann Dominique, ed. Academic Press. Chapter 2010; vol. 1: p. 3-7.
34. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin. North Am 1997; 44: 973-89.
35. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294-9.
36. Riggi N, Suva M, Stamenkovic I. Ewing's sarcoma origin: from duel to duality. Expert Rev Anticancer Ther 2009; 9: 1025-30.
37. Khoury J. Ewing's sarcoma family of tumors. In Bone cancer: progression and therapeutic approaches. Heymann Dominique, Ed. Academic Press. Chapter 2010; vol. 20: pp. 235-50.
38. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001; 84: 951-8.
39. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001; 12: 459-65.
40. Kanamori M, Matsui H, Maeda A, Yudoh K, Tsuji H, Tatezaki S. Effects of ethane-1-hydroxy-1, 1 diphosphonate on Dunn osteosarcoma cells. J Exp Clin Cancer Res 1997; 16: 39-43.
41. Kubista B, Trieb K, Sevelda F, et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006; 24: 1145-52.
42. Horie N, Murata H, Nishigaki Y, et al. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett 2006; 238: 111-8.
43. Tenta R, Pitulis N, Tiblalexi D, et al. Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm Metab Res 2008; 40: 737-45.
44. Frith JC, Mönkkönen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12: 1358-67.
45. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003; 33: 216-28.
46. Inoue R, Matsuki N, Jing G, Kanematsu T, Abe K, Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol 2005; 146: 633-41.
47. Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007; 7 1: 333-43.
48. Iguchi T, Miyakawa Y, Saito K, et al. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 2007; 31: 285-91.
49. Molinuevo MS, Bruzzone L, Cortizo AM. Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur J Pharmacol 2007; 562: 28-33.
50. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004; 42: 410-5.
51. Xin ZF, Kim YK, Jung ST. Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 2009; 28: 105.
52. Heikkilä P, Teronen O, Hirn MY, et al. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J Surg Res 2003; 111: 45-52.
53. Vazquez G, Santillan G, Boland R, Roldán E, Pérez-Lloret A. Modulation of cytosolic calcium levels in osteoblast-like osteosarcoma cells by olpadronate and its amino-derivative IG-9402. Calcif Tissue Int 2003; 72: 215-21.
54. Ory B, Moriceau G, Trichet V, et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008; 12: 928-41.
55. Wingen F, Sterz H, Blum H, et al. Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. J Cancer Res Clin Oncol 1986; 111: 209-19.
56. Ory B, Heymann M, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005; 104: 2522-9.
57. Dass CR, Choong PFM. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007; 6: 3263-70.
58. Koto K, Horie N, Kimura S, et al. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 2009; 274: 271-8.
59. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009; 15: 3451-61.
60. Labrinidis A, Hay S, Liapis V, Findlay DM, Evdokiou A. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int J Cancer 2010; 127: 345-54.
61. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998; 27: 38-41.
62. Tenta R, Sourla A, Lembessis P, Koutsilieris M. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res 2006; 26: 283-91.
63. Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli F. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol 2007; 249: 63-72.
64. Muraro M, Mereuta OM, Saglio F, et al. Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study. Cell Immunol 2008; 253: 71-80.
65. Chauvin C, Philippeau J, Hémont C, et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res 2008; 68: 9433-40.
66. Benassi MS, Chiechi A, Ponticelli F, et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 2007; 250: 194-205.
67. Murayama T, Kawasoe Y, Yamashita Y, et al. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res 2008; 28: 2147-54.
68. Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol 2008; 62: 111-6.
69. Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005; 37(1): 74-86.
70. Horie N, Murata H, Kimura S, et al. Combined effects of a thirdgeneration bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 2007; 96: 255-61.
71. Dickerson ME, Page RL, LaDue TA, et al. Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern Med 2001; 15: 120-4.
72. Ashton JA, Farese JP, Milner RJ, Lee-Ambrose LM, van Gilder JM. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005; 66: 885-91.
73. Farese JP, Ashton J, Milner R, Ambrose L, Van Gilder J. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim 2004; 40: 113-7.
74. Tomlin JL, Sturgeon C, Pead MJ, Muir P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000; 147: 129-32.
75. Fan TM, de Lorimier L, O'Dell-Anderson K, Lacoste HI, Charney SC. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med 2007; 21: 431-9.
76. Fan TM, de Lorimier LP, Garrett LD, Lacoste HI. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med 2008; 22: 380-7.
77. Spugnini EP, Vincenzi B, Caruso G, et al. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. J Small Anim Pract 2009; 50: 44-46.
78. Fan TM, Charney SC, de Lorimier LP, et al. Double-blind placebo- controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med 2009; 23: 152-60.
79. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 2003; 14: 767-71.
80. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005; 15; 104: 1713-20.
81. Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007; 64: 2334-50.
82. Siden H. The boy who refused an IV: a case report of subcutaneous clodronate for bone pain in a child with Ewing Sarcoma. J Med Case Reports 2007; 1: 7.
83. Lichtenstein L, Jaffe HL. Chondrosarcoma of bone. Am J Pathol 1943; 19(4): 553-89.
84. Dahlin D, Unni K. Bone tumors: general aspects and data on 8542 cases. 4th ed. Sprinfield: IL: Charles C Thomas 1986.
85. Streibuerger A, Hardes J, Gosheger G. Chondrosarcoma of bone: diagnosis and therapy. In Bone cancer: progression and therapeutic approaches. Heymann Dominique, ed. Academic Press. Chapter 2010; 33: 407-15.
86. Fiorenza F, Abudu A, Grimer RJ, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002; 84: 93-9.
87. Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer 1980; 45: 149-57.
88. Lai T, Hsu S, Li T, Hsu H, Lin J, Hsu C, et al. Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin 2007; 28: 1231-5.
89. Susa M, Morii T, Yabe H, et al. Alendronate inhibits growth of high-grade chondrosarcoma cells. Anticancer Res 2009; 29: 1879-88.
90. Gouin F, Ory B, Rédini F, Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006; 119: 980-4.
91. Kubo T, Shimose S, Matsuo T, et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 2006; 24: 1138-44.
92. Montella L, Addeo R, Faiola V, et al. Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. J Exp Clin Cancer Res 2009; 28: 7.
93. Montella L, Merola C, Merola G, Petillo L, Palmieri G. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 2009; 27: 110-3.
94. Allaudin S, Alan GT, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: e1-8.
95. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis 2009; 15: 527-37.
96. Corso A, Ferreti E, Lazzarino M. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 2005; 10: 215-24.
97. Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunther 2008; 57: 1451-9.
98. Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumorassociated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008; 788-99.
99. Ribatti D, Maruotti, Nico B, et al. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol Rep 2008: 1109-12.
100. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13: 4482-6.
101. Bäckman U, Svensson A, Chritofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth with interfering with tumour angiogenesis. Anticancer Res 2008: 28: 1551-7.
102. Cackowski FC, Roodman GD. Perspective on the osteoclast: an angiogenic cell? Ann N Y Acad Sci 2007; 1117: 12-25.
103. Holen I, Coleman RE. Bisphosphonates as Treatment of Bone Metastases. Curr Pharm Des 2010; 15(11): 1262-71.
104. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.
105. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8(21): 1929-44.